180 Life Sciences received a response from the MHRA regarding a meeting held to propose a Phase 3 clinical trial for the use of adalimumab as a therapy for Dupuytren's contracture; MHRA agreed with proposed endpoints and stated that Phase 3 study results are needed for marketing authorization.